Results 261 to 270 of about 462,488 (300)
Some of the next articles are maybe not open access.
Antihyperglycemic agents and cardiovascular outcomes
Current Opinion in Cardiology, 2017To summarize cardiovascular outcome trials (CVOTs) with antihyperglycemic agents conducted since 2008 US Food and Drug Administration guidance.A series of large CVOTs since 2008 have included patients with type 2 diabetes (T2D), who are otherwise treated according to standard of care.
Harpreet S, Bajaj +2 more
openaire +2 more sources
Novel Antiplatelet Agents in Cardiovascular Medicine
Current Treatment Options in Cardiovascular Medicine, 2015Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker, particularly clopidogrel, has been the standard of therapy for secondary prevention in patients with acute coronary syndromes and patients treated with percutaneous coronary intervention.
Rahil, Rafeedheen +4 more
openaire +2 more sources
Naturoceutical Agents in the Management of Cardiovascular Disease
American Journal of Cardiovascular Drugs, 2002During the past decade, complementary and alternative medicine (CAM) has grown in attractiveness to the Western public, and in recognition by practitioners of traditional medicine. The incorporation of effective CAM therapies into traditional practice is termed 'integrative medicine'. One form of CAM demonstrating exponential growth through mass public
openaire +2 more sources
Therapeutic potential of chalcones as cardiovascular agents
Life Sciences, 2016Cardiovascular diseases are the leading cause of death affecting 17.3 million people across the globe and are estimated to affect 23.3 million people by year 2030. In recent years, about 7.3 million people died due to coronary heart disease, 9.4 million deaths due to high blood pressure and 6.2 million due to stroke, where obesity and atherosclerotic ...
Debarshi Kar Mahapatra +1 more
openaire +2 more sources
Urokinase-a Very Popular Cardiovascular Agent
Recent Patents on Cardiovascular Drug Discovery, 2008Urokinase (UK) [EC 3.4.99.26] is a serine protease that activates plasminogen to plasmin, which in turn degrades fibrin clots. Hence, UK finds its value as an important anti-thromboembolic drug. Plasmin has diverse physiological roles apart from its fibrinolytic role in the regulation of blood clotting.
Adinarayana, Kunamneni +4 more
openaire +2 more sources
Cardiovascular Effects of Intravenous Anesthetic Agents
1985The most commonly used anesthetic agents of this kind are the barbiturates. The duration of action of these agents is tied to their fat solubility. Since the thiobarbiturates are more fat soluble (classified as ultra-short acting), they provide a surgical plane of anesthesia for less time than the short acting agents such as pentobarbital sodium.
openaire +1 more source
Methods for Identifying Cardiovascular Agents: A Review
Recent Patents on Cardiovascular Drug Discovery, 2006Basic and clinical investigation into many of the diverse aspects of cardiovascular drug discovery employs varied approaches aimed at determining physiologic and pathophysiologic efficacy of candidate agents for therapeutic utility with the ultimate hope of identifying those agents capable of exerting salutary influence upon cardiac and vascular ...
openaire +2 more sources
[Pregnancy and cardiovascular agents].
Annales de cardiologie et d'angeiologie, 1993Any treatment used in pregnant women must take into account the effects of the substance in question of the fetus and the particular sensitivity of the latter during the first three months of development. The majority of drugs used in cardiology can be prescribed during pregnancy: digitalis preparations, furosemide, certain beta-blockers, verapamil ...
openaire +1 more source